Barry A Borlaug1, Gregory D Lewis2, Steven E McNulty2, Marc J Semigran2, Martin LeWinter2, Horng Chen2, Grace Lin2, Anita Deswal2, Kenneth B Margulies2, Margaret M Redfield2. 1. From the Department of Medicine, Division of Cardiology, Mayo Clinic, Rochester, MN (B.A.B., H.C., G.L., M.M.R.); Department of Medicine, Massachusetts General Hospital, Boston (G.D.L., M.J.S.); Department of Medicine, Duke Clinical Research Institute, Durham, NC (S.E.M.); Department of Medicine, Cardiology Unit, University of Vermont College of Medicine, Burlington (M.L.W.); Department of Medicine, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, TX (A.D.); and Department of Medicine, University of Pennsylvania, Translational Research Center, Philadelphia (K.B.M.). borlaug.barry@mayo.edu. 2. From the Department of Medicine, Division of Cardiology, Mayo Clinic, Rochester, MN (B.A.B., H.C., G.L., M.M.R.); Department of Medicine, Massachusetts General Hospital, Boston (G.D.L., M.J.S.); Department of Medicine, Duke Clinical Research Institute, Durham, NC (S.E.M.); Department of Medicine, Cardiology Unit, University of Vermont College of Medicine, Burlington (M.L.W.); Department of Medicine, Michael E. DeBakey VA Medical Center and Department of Medicine, Baylor College of Medicine, Houston, TX (A.D.); and Department of Medicine, University of Pennsylvania, Translational Research Center, Philadelphia (K.B.M.).
Abstract
BACKGROUND: Early studies showed beneficial effects of phosphodiesterase 5 inhibitors on cardiovascular function in heart failure (HF) patients, but the RELAX trial observed no improvement in exercise capacity with sildenafil treatment in subjects with HF and preserved ejection fraction. METHODS AND RESULTS:A subgroup of participants in the RELAX trial (n=48) underwentcomprehensive noninvasive cardiovascular assessment before and after treatment with sildenafil or placebo in a prospective ancillary study. Left ventricular contractility was assessed by peak power index and stroke work index. Systemic arterial load was assessed by arterial elastance (Ea) and right ventricular afterload by pulmonary artery systolic pressure. Endothelial function was assessed by reactive hyperemia index after upper arm cuff occlusion. Compared with placebo (n=25), sildenafil (n=23) decreased Ea (-0.29±0.28 mm Hg/mL versus +0.02±0.29, P=0.008) and tended to improve reactive hyperemia index (+0.30±0.45 versus -0.17±0.30, P=0.054). In contrast, left ventricular contractility was reduced by 11% to 16% with sildenafil compared with placebo (ΔPWR/EDV -52±70 versus +0±40 mm Hg/s, P=0.006; ΔSW/EDV +0.3±5.8 versus -6.0±5.1 mm Hg, P=0.04). Sildenafil had no effect on pulmonary artery systolic pressure. CONCLUSIONS: In subjects with HF and preserved ejection fraction, sildenafil displayed opposing effects on ventricular and vascular function. We speculate that beneficial effects of phosphodiesterase 5 inhibitors in the systemic vasculature and endothelium were insufficient to improve clinical status or that the deleterious effects on left ventricular function offset any salutary vascular effects, contributing to the absence of benefit observed with sildenafil in subjects with HF and preserved ejection fraction in the RELAX trial. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
RCT Entities:
BACKGROUND: Early studies showed beneficial effects of phosphodiesterase 5 inhibitors on cardiovascular function in heart failure (HF) patients, but the RELAX trial observed no improvement in exercise capacity with sildenafil treatment in subjects with HF and preserved ejection fraction. METHODS AND RESULTS: A subgroup of participants in the RELAX trial (n=48) underwent comprehensive noninvasive cardiovascular assessment before and after treatment with sildenafil or placebo in a prospective ancillary study. Left ventricular contractility was assessed by peak power index and stroke work index. Systemic arterial load was assessed by arterial elastance (Ea) and right ventricular afterload by pulmonary artery systolic pressure. Endothelial function was assessed by reactive hyperemia index after upper arm cuff occlusion. Compared with placebo (n=25), sildenafil (n=23) decreased Ea (-0.29±0.28 mm Hg/mL versus +0.02±0.29, P=0.008) and tended to improve reactive hyperemia index (+0.30±0.45 versus -0.17±0.30, P=0.054). In contrast, left ventricular contractility was reduced by 11% to 16% with sildenafil compared with placebo (ΔPWR/EDV -52±70 versus +0±40 mm Hg/s, P=0.006; ΔSW/EDV +0.3±5.8 versus -6.0±5.1 mm Hg, P=0.04). Sildenafil had no effect on pulmonary artery systolic pressure. CONCLUSIONS: In subjects with HF and preserved ejection fraction, sildenafil displayed opposing effects on ventricular and vascular function. We speculate that beneficial effects of phosphodiesterase 5 inhibitors in the systemic vasculature and endothelium were insufficient to improve clinical status or that the deleterious effects on left ventricular function offset any salutary vascular effects, contributing to the absence of benefit observed with sildenafil in subjects with HF and preserved ejection fraction in the RELAX trial. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00094302.
Authors: Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart Journal: J Am Soc Echocardiogr Date: 2005-12 Impact factor: 5.251
Authors: Theophilus E Owan; David O Hodge; Regina M Herges; Steven J Jacobsen; Veronique L Roger; Margaret M Redfield Journal: N Engl J Med Date: 2006-07-20 Impact factor: 91.245
Authors: Gregory D Lewis; Justine Lachmann; Janice Camuso; John J Lepore; Jordan Shin; Maryann E Martinovic; David M Systrom; Kenneth D Bloch; Marc J Semigran Journal: Circulation Date: 2006-12-18 Impact factor: 29.690
Authors: Barry A Borlaug; Vojtech Melenovsky; Tricia Marhin; Patricia Fitzgerald; David A Kass Journal: Circulation Date: 2005-10-25 Impact factor: 29.690
Authors: Carolyn S P Lam; Véronique L Roger; Richard J Rodeheffer; Francesca Bursi; Barry A Borlaug; Steve R Ommen; David A Kass; Margaret M Redfield Journal: Circulation Date: 2007-04-02 Impact factor: 29.690
Authors: W Gregory Hundley; Ersin Bayram; Craig A Hamilton; Eric A Hamilton; Timothy M Morgan; Stephen N Darty; Kathryn P Stewart; Kerry M Link; David M Herrington; Dalane W Kitzman Journal: Am J Physiol Heart Circ Physiol Date: 2006-11-03 Impact factor: 4.733
Authors: Eiki Takimoto; Diego Belardi; Carlo G Tocchetti; Susan Vahebi; Gianfrancesco Cormaci; Elizabeth A Ketner; An L Moens; Hunter C Champion; David A Kass Journal: Circulation Date: 2007-04-09 Impact factor: 29.690
Authors: Barry A Borlaug; Horng Chen; Grace Lin; Margaret M Redfield; Gregory D Lewis; Marc J Semigran; Steven E McNulty; Martin LeWinter; Anita Deswal; Kenneth B Margulies Journal: Circ Heart Fail Date: 2015-07 Impact factor: 8.790
Authors: Sanjiv J Shah; Dalane W Kitzman; Barry A Borlaug; Loek van Heerebeek; Michael R Zile; David A Kass; Walter J Paulus Journal: Circulation Date: 2016-07-05 Impact factor: 29.690
Authors: Yogesh N V Reddy; Masaru Obokata; Katlyn E Koepp; Alexander C Egbe; Brandon Wiley; Barry A Borlaug Journal: Circ Res Date: 2019-01-18 Impact factor: 17.367
Authors: Ravi B Patel; Rupal Mehta; Margaret M Redfield; Barry A Borlaug; Adrian F Hernandez; Sanjiv J Shah; Ruth F Dubin Journal: J Card Fail Date: 2020-01-11 Impact factor: 5.712
Authors: Yogesh N V Reddy; Gregory D Lewis; Sanjiv J Shah; Martin LeWinter; Marc Semigran; Victor G Davila-Roman; Kevin Anstrom; Adrian Hernandez; Eugene Braunwald; Margaret M Redfield; Barry A Borlaug Journal: Circ Heart Fail Date: 2017-05 Impact factor: 8.790